Cure8 research brief
A noninvasive, explainable model that combines CT enterography radiomics with CRP could make it easier to monitor mucosal healing in small‑bowel Crohn’s disease without repeated invasive enteroscopy, especially after biologic therapy.
Clinicians and radiologists involved in IBD monitoring, researchers in AI/radiomics and IBD biomarkers, and patients with small‑bowel Crohn’s disease receiving biologic therapy who need mucosal healing assessment.
This study used retrospective and a small prospective cohort to train and test a multimodal model. CRP emerged as the only clinical predictor; selected CTE radiomics features were combined with CRP using an XGBoost algorithm. The model was interpreted with SHAP values and showed AUCs ~0.82–0.86 across cohorts, and the multimodal model outperformed CRP alone.
The model aims to be a clinical decision‑support tool to noninvasively assess mucosal healing, but implementation would require further validation, integration with clinical workflows, and assessment of impact on patient outcomes.
Structured content depth is 'abstract' — the summary is grounded in the article abstract. The prospective cohort was small (n=20); additional larger, diverse validations and workflow studies are needed before routine clinical use. The study used CTE radiomics and CRP specifically; findings don’t directly apply to other imaging modalities or biomarker panels.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: the Natural Science Foundation of Anhui Province - 2308085MH241
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...
